Subtopic Deep Dive
Tumor Lysis Syndrome Risk Stratification
Research Guide
What is Tumor Lysis Syndrome Risk Stratification?
Tumor Lysis Syndrome risk stratification classifies patients with hematologic malignancies into low, intermediate, and high TLS risk groups using criteria like tumor burden, laboratory values, and clinical factors to guide prophylaxis before chemotherapy.
Cairo-Bishop criteria define laboratory TLS by ≥25% changes or 1.5x ULN in uric acid, potassium, phosphate, or calcium from baseline within 3 days before to 7 days after chemotherapy (Cairo et al., 2010, 539 citations). Clinical TLS adds renal, cardiac, or neurologic complications. Guidelines from Jones et al. (2015, 199 citations) and Horie et al. (2017, 77 citations) refine risk scoring for adults and children.
Why It Matters
Risk stratification using Cairo-Bishop criteria prevents TLS complications like acute kidney injury in high-burden lymphomas by targeting rasburicase or allopurinol to intermediate-high risk patients, reducing hospitalization costs (Cairo et al., 2010; Jones et al., 2015). FLORENCE trial showed febuxostat noninferior to allopurinol in TLS prevention for hematologic malignancies at intermediate-high risk (Spina et al., 2015). Models incorporating tumor bulk and renal function optimize prophylaxis, avoiding overtreatment in low-risk cases (McBride and Westervelt, 2012).
Key Research Challenges
Expanding TLS Risk to Solid Tumors
TLS risk models validated mainly in hematologic malignancies require adaptation for solid tumors with lower incidence but rising reports post-immunotherapy. McBride and Westervelt (2012) highlight expanded criteria needs. Validation studies across tumor types remain limited.
Personalizing Prophylaxis Dosing
Balancing rasburicase efficacy against methemoglobinemia risk in G6PD-deficient patients complicates stratification (Sonbol et al., 2012). Trials like FLORENCE compare agents but lack head-to-head data for all risk groups (Spina et al., 2015). Renal function integration per Horie et al. (2017) adds complexity.
Integrating Machine Learning Models
Traditional scoring like Cairo-Bishop overlooks dynamic markers; ML models need prospective validation. Belay et al. (2017) note lab marker gaps. Alakel et al. (2017) call for predictive algorithms beyond static criteria.
Essential Papers
Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus
Mitchell S. Cairo, Bertrand Coiffier, Alfred Reiter et al. · 2010 · British Journal of Haematology · 539 citations
Summary Tumour lysis syndrome (TLS) is a life‐threatening oncological emergency characterized by metabolic abnormalities including hyperuricaemia, hyperphosphataemia, hyperkalaemia and hypocalcaemi...
Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology
Gail Jones, Andrew Will, Graham Jackson et al. · 2015 · British Journal of Haematology · 199 citations
The guideline group was selected to be representative of UK-based medical experts. Recommendations are based on review of the literature using MEDLINE and PUBMED up to December 2013 under the headi...
Tumor Lysis Syndrome in Patients with Hematological Malignancies
Yohannes Belay, Ketsela Yirdaw, Bamlaku Enawgaw · 2017 · Journal of Oncology · 115 citations
Tumor lysis syndrome is a metabolic complication that may follow the initiation of cancer therapy. It commonly occurs in hematological malignant patients particularly non-Hodgkin’s lymphoma and acu...
Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase
Nael Alakel, Jan Moritz Middeke, Johannes Schetelig et al. · 2017 · OncoTargets and Therapy · 102 citations
Tumor lysis syndrome (TLS) is a potentially life-threatening condition that occurs in oncologic and hematologic patients with large tumor burden, either due to cytotoxic therapy or, less commonly, ...
FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk
Michele Spina, Zoltán Nagy, Josep‐María Ribera et al. · 2015 · Annals of Oncology · 84 citations
Recognizing and managing the expanded risk of tumor lysis syndrome in hematologic and solid malignancies
Ali McBride, Peter Westervelt · 2012 · Journal of Hematology & Oncology · 82 citations
Guidelines for treatment of renal injury during cancer chemotherapy 2016
Shigeo Horie, Mototsugu Oya, Masaomi Nangaku et al. · 2017 · Clinical and Experimental Nephrology · 77 citations
Advances in cancer drug therapy have led to improvements in the outcomes of cancer patients, as well as increasing numbers of patients undergoing anticancer chemotherapy and molecularly targeted dr...
Reading Guide
Foundational Papers
Start with Cairo et al. (2010, 539 citations) for core risk criteria and prophylaxis consensus, then McBride and Westervelt (2012, 82 citations) for solid tumor expansion.
Recent Advances
Study Jones et al. (2015, 199 citations) for UK hematology guidelines and Spina et al. (2015, 84 citations) FLORENCE trial on febuxostat vs allopurinol.
Core Methods
Apply Cairo-Bishop lab/clinical criteria, incorporate tumor bulk and renal markers per Horie et al. (2017), use rasburicase for high-risk with G6PD screening (Alakel et al., 2017).
How PapersFlow Helps You Research Tumor Lysis Syndrome Risk Stratification
Discover & Search
Research Agent uses searchPapers('Tumor Lysis Syndrome risk stratification Cairo-Bishop') to retrieve Cairo et al. (2010) with 539 citations, then citationGraph reveals Jones et al. (2015) as top citer, and findSimilarPapers surfaces Spina et al. (2015) FLORENCE trial for prophylaxis comparisons.
Analyze & Verify
Analysis Agent runs readPaperContent on Cairo et al. (2010) to extract risk criteria tables, verifies prophylaxis claims via verifyResponse (CoVe) against Jones et al. (2015), and uses runPythonAnalysis to plot TLS incidence rates from Belay et al. (2017) data with GRADE B evidence for hematologic risks.
Synthesize & Write
Synthesis Agent detects gaps in solid tumor stratification from McBride and Westervelt (2012), flags contradictions between rasburicase risks in Sonbol et al. (2012) and Alakel et al. (2017), then Writing Agent applies latexEditText for risk table edits, latexSyncCitations for 10-paper bibliography, and latexCompile for oncology review exportMermaid flowchart of Cairo-Bishop tiers.
Use Cases
"Extract TLS risk scores from Cairo 2010 and compute incidence stats for lymphomas"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis(pandas on lab data) → matplotlib incidence plot with GRADE grading.
"Draft LaTeX section comparing FLORENCE trial prophylaxis to guidelines"
Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations(Spina 2015, Jones 2015) → latexCompile PDF.
"Find code for TLS prediction models from recent papers"
Research Agent → paperExtractUrls → Code Discovery → paperFindGithubRepo → githubRepoInspect for Cairo-Bishop ML implementations.
Automated Workflows
Deep Research workflow scans 50+ TLS papers via searchPapers, structures Cairo-Bishop evolution report with citationGraph. DeepScan applies 7-step CoVe to validate Spina et al. (2015) claims against Horie et al. (2017). Theorizer generates hypotheses on ML-enhanced stratification from Belay et al. (2017) markers.
Frequently Asked Questions
What is the Cairo-Bishop definition of TLS risk?
Cairo-Bishop classifies laboratory TLS by ≥25% or 1.5x ULN rises in two or more of uric acid, potassium, phosphate, or calcium fall within 3 days pre- to 7 days post-therapy (Cairo et al., 2010).
What methods stratify TLS risk?
Risk tiers use tumor type/burden, baseline labs (creatinine, uric acid), and factors like dehydration; low/intermediate/high per Cairo panel and Jones guidelines (Cairo et al., 2010; Jones et al., 2015).
What are key papers on TLS stratification?
Cairo et al. (2010, 539 citations) provides consensus criteria; Jones et al. (2015, 199 citations) UK guidelines; Spina et al. (2015, 84 citations) FLORENCE prophylaxis trial.
What open problems exist in TLS risk models?
Lack of prospective ML validation beyond Cairo-Bishop; solid tumor adaptation; G6PD-safe prophylaxis personalization (McBride and Westervelt, 2012; Sonbol et al., 2012).
Research Methemoglobinemia and Tumor Lysis Syndrome with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Tumor Lysis Syndrome Risk Stratification with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers